Open Access

Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count

  • Authors:
    • Dongdong Wang
    • Xiaofei Zheng
    • Yang Yang
    • Xiao Chen
  • View Affiliations

  • Published online on: July 8, 2019     https://doi.org/10.3892/etm.2019.7747
  • Pages: 1786-1792
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Linezolid was approved by the Food and Drug Administration for the treatment of serious infections. However, patients with serious frequently develop shock, and it is currently elusive whether shock affects the pharmacokinetics of linezolid. The aim of the present study was to explore whether the pharmacokinetics of linezolid are different among patients with various types of shock or patients without shock and whether potential confounders are involved in their outcomes. A population pharmacokinetic analysis using a non‑linear mixed‑effects model was performed to examine the pharmacokinetics of patients with different types of shock or patients without shock. The pharmacokinetics of linezolid in patients with different types of shock or patients without shock was described by a one‑compartment model. In our results, the patients with different types of shock or patients without shock demonstrated no differences in pharmacokinetics, whereas the platelet count was identified as a significant influencing factor. The results demonstrated that the pharmacokinetics of linezolid exhibited no significant differences among patients with different types of shock or patients without shock, whereas the platelet count significantly affected the clearance rate of linezolid.

References

1 

Ashtekar DR, Costa-Periera R, Shrinivasan T, Iyyer R, Vishvanathan N and Rittel W: Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 14:465–471. 1991. View Article : Google Scholar : PubMed/NCBI

2 

Jones RN, Johnson DM and Erwin ME: In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 40:720–726. 1996. View Article : Google Scholar : PubMed/NCBI

3 

Kaatz GW and Seo SM: In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 40:799–801. 1996. View Article : Google Scholar : PubMed/NCBI

4 

Meagher AK, Forrest A, Rayner CR, Birmingham MC and Schentag JJ: Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 47:548–553. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T and Rom WN: Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest. 134:187–192. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E and Moreno S: Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 56:180–185. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD and Shim TS: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother. 58:701–704. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Cynamon MH, Klemens SP, Sharpe CA and Chase S: Activities of several novel oxazolidinones against mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 43:1189–1191. 1999. View Article : Google Scholar : PubMed/NCBI

9 

Molicotti P, Ortu S, Bua A, Cannas S, Sechi LA and Zanetti S: In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol. 29:275–280. 2006.PubMed/NCBI

10 

Sood R, Bhadauriya T, Rao M, Gautam R, Malhotra S, Barman TK, Upadhyay DJ and Rattan A: Antimycobacterial activities of oxazolidinones: A review. Infect Disord Drug Targets. 6:343–354. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP and Kuti JL: Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 55:3393–3398. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Sazdanovic P, Jankovic SM, Kostic M, Dimitrijevic A and Stefanovic S: Pharmacokinetics of linezolid in critically ill patients. Expert Opin Drug Metab Toxicol. 12:595–600. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Buerger C, Plock N, Dehghanyar P, Joukhadar C and Kloft C: Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 50:2455–2463. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Calzada Y, Jordan I, Vila-Perez D, Cambra FJ and Munoz-Almagro C: Pleuropneumonia and septic shock due to multiresistant Streptococcus pneumoniae serotype 19A treated with linezolid. An Pediatr (Barc). 81:e22–23. 2014.(In Spanish). View Article : Google Scholar : PubMed/NCBI

15 

De Bels D, Garcia-Filoso A, Jeanmaire M, Preseau T, Miendje Deyi VY and Devriendt J: Successful treatment with linezolid of septic shock secondary to methicillin-resistant Staphylococcus aureus arthritis. J Antimicrob Chemother. 55:812–813. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Rac H, Bojikian KD, Lucar J and Barber KE: Successful treatment of necrotizing fasciitis and streptococcal toxic shock syndrome with the addition of linezolid. Case Rep Infect Dis. 2017:57207082017.PubMed/NCBI

17 

Stevens DL, Wallace RJ, Hamilton SM and Bryant AE: Successful treatment of staphylococcal toxic shock syndrome with linezolid: A case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 42:729–730. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Wang DD, Lu JM, Li Q and Li ZP: Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther. 43:476–483. 2018. View Article : Google Scholar : PubMed/NCBI

19 

Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations. J Clin Pharm Ther. 41:310–328. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estevez R, Canton E and Gobernado M: In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter. 19:252–257. 2006.PubMed/NCBI

21 

Sweeney MT and Zurenko GE: In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother. 47:1902–1906. 2003. View Article : Google Scholar : PubMed/NCBI

22 

Beitdaghar M, Ahmadrajabi R, Karmostaji A and Saffari F: In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates. Wien Med Wochenschr. 169:215–221. 2019. View Article : Google Scholar : PubMed/NCBI

23 

Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 17:479–501. 2003. View Article : Google Scholar : PubMed/NCBI

24 

Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY and Roberts JA: Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: Comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother. 71:464–470. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Rayner CR, Forrest A, Meagher AK, Birmingham MC and Schentag JJ: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 42:1411–1423. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Wang DD, Lu JM, Li YZ, Li Q and Li ZP: Population pharmacokinetics of sirolimus in pediatric tuberous sclerosis complex: From real world study. Int J Clin Exp Med. 11:12302–12309. 2018.

27 

Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, Chen C and Li Z: Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 74:921–930. 2018. View Article : Google Scholar : PubMed/NCBI

28 

Gong Y, Chen Y, Li Q and Li Z: Population pharmacokinetic analysis of digoxin in Chinese neonates and infants. J Pharmacol Sci. 125:142–149. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, Wu D, Zhu Y, Wang Y and Chen C: Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur J Clin Pharmacol. 69:1223–1233. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Andrews LM, Hesselink DA, van Gelder T, Koch BC, Cornelissen EA, Bruggemann RJ, van Schaik RH, de Wildt SN, Cransberg K and de Winter BC: A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin Pharmacokinet. 57:475–489. 2018. View Article : Google Scholar : PubMed/NCBI

31 

Yu ZC, Zhou PJ, Wang XH, Francoise B, Xu D, Zhang WX and Chen B: Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta Pharmacol Sin. 38:1566–1579. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Chen B, Shi HQ, Liu XX, Zhang WX, Lu JQ, Xu BM and Chen H: Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 42:679–688. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Chevillard L, Sabo N, Tod M, Labat L, Chasport C, Chevaleyre C, Thibaut F, Barre J, Azuar J, Questel F, et al: Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. Fundam Clin Pharmacol. 32:239–248. 2018. View Article : Google Scholar : PubMed/NCBI

34 

Plock N, Buerger C, Joukhadar C, Kljucar S and Kloft C: Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos. 35:1816–1823. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, D., Zheng, X., Yang, Y., & Chen, X. (2019). Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count. Experimental and Therapeutic Medicine, 18, 1786-1792. https://doi.org/10.3892/etm.2019.7747
MLA
Wang, D., Zheng, X., Yang, Y., Chen, X."Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count". Experimental and Therapeutic Medicine 18.3 (2019): 1786-1792.
Chicago
Wang, D., Zheng, X., Yang, Y., Chen, X."Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1786-1792. https://doi.org/10.3892/etm.2019.7747